SHERP

(188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study

Cited 0 time in webofscience Cited 17 time in scopus
Authors
Lambert, Bieke; Bacher, Klaus; Defreyne, Luc; Van Vlierberghe, Hans; Jeong, Jae Min; Wang, Rong Fu; van Meerbeeck, Jan; Smeets, Peter; Troisi, Roberto; Thierens, Hubert; De Vos, Filip; Van de Wiele, Christophe
Issue Date
2005-12-08
Publisher
Springer Verlag
Citation
Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):344-52. Epub 2005 Dec 7.
Keywords
AgedAged, 80 and overCarcinoma, Hepatocellular/*metabolism/*radiotherapyDose-Response Relationship, DrugDose-Response Relationship, RadiationDrug Administration ScheduleFeasibility StudiesHalf-LifeHumansIodized Oil/*pharmacokinetics/*therapeutic useLiver Neoplasms/*metabolism/*radiotherapyMetabolic Clearance RateMiddle AgedOrgan SpecificityOrganometallic Compounds/*pharmacokinetics/*therapeutic useRadiation DosageRadiopharmaceuticals/adverse effects/pharmacokinetics/therapeutic useTissue DistributionTreatment OutcomeWhole-Body Counting
Abstract
PURPOSE: The aim of this study was to investigate the feasibility of administering increasing activities of (188)Re-4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/lipiodo l ((188)Re-HDD/lipiodol) for the treatment of hepatocellular carcinoma (HCC) in patients with well-compensated cirrhosis.METHODS: The activity levels were increased by 1.1 GBq/step after a 6-week interval without unacceptable adverse events in at least five consecutive patients. Absorbed doses to the various organs were calculated according to the MIRD formalism, based on three gamma-scintigraphic studies. Response was assessed by means of MRI and alpha-fetoprotein (AFP) monitoring.RESULTS: Thirty-five treatments were carried out in 28 patients. Activities from 4.8 to 7.0 GBq (188)Re-HDD/lipiodol were administered via a transfemoral catheter. The mean absorbed dose to the liver (including tumour) was 7.6+/-2.2, 9.8+/-4.9 and 15.2+/-4.9 Gy for the 4.8-, 5.9- and 7.0-GBq groups, respectively. Treatment was well tolerated at all activity levels. Further escalation of the administered activity was not feasible owing to limitations related to the radiolabelling procedure. Response assessment on MRI showed partial response, stable disease and disease progression in 1, 28 and 2 assessable treatments, respectively. In 8 of 17 treatment sessions with an initially elevated AFP, a reduction ranging from 19% to 97% was observed 6 weeks later.CONCLUSION: Following the intra-arterial administration of 4.8-7.0 GBq (188)Re-HDD/lipiodol in patients with HCC and well-compensated liver cirrhosis, no severe adverse events occurred. Further escalation was not feasible owing to limitations in the radiolabelling procedure.
ISSN
1619-7070 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16333675

http://hdl.handle.net/10371/24089
DOI
https://doi.org/10.1007/s00259-005-1954-1
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Nuclear Medicine (핵의학전공)Journal Papers (저널논문_핵의학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse